Comparative Pharmacology
Head-to-head clinical analysis: IHEEZO versus PREDNISOLONE EYE DROPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IHEEZO versus PREDNISOLONE EYE DROPS.
IHEEZO vs Prednisolone Eye Drops
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iheezo (phentolamine ophthalmic solution) is an alpha-adrenergic antagonist that inhibits sympathetic tone to the iris dilator muscle, preventing mydriasis and facilitating pupil constriction during ocular surgery.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
1 drop in the affected eye(s) 3 times daily as needed for relief of ocular discomfort. For optimal use, administer at least 10 minutes apart from other ophthalmic medications.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
None Documented
None Documented
The terminal elimination half-life of proparacaine is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, resulting in a very short duration of systemic exposure.
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
IHEEZO (proparacaine) is predominantly metabolized by plasma esterases; less than 5% is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Category C
Category A/B
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid